Safety and Efficacy of Long-term Gantenerumab Treatment in Dominantly Inherited Alzheimer's Disease: An Open-label Extension of the Phase 2/3 Multicentre, Randomised, Double-blind, Placebo-controlled Platform Dian-tu Trial

Bateman, Randall J, Li, Yan, McDade, Eric M, Llibre-Guerra, Jorge J, Clifford, David B, Atri, Alireza, Mills, Susan L, Santacruz, Anna M, Wang, Guoqiao, Supnet, Charlene, Benzinger, Tammie L S, Gordon, Brian A, Ibanez, Laura, Klein, Gregory, Baudler, Monika, Doody, Rachelle S, Delmar, Paul, Kerchner, Geoffrey A, Bittner, Tobias, Wojtowicz, Jakub, Bonni, Azad, Fontoura, Paulo, Hofmann, Carsten, Kulic, Luka, Hassenstab, Jason, Aschenbrenner, Andrew J, Perrin, Richard J, Cruchaga, Carlos, Renton, Alan E, Xiong, Chengjie, Goate, Alison A, Morris, John C, Holtzman, David M, Snider, B Joy, Mummery, Catherine, Brooks, William S, Wallon, David, Berman, Sarah B, Roberson, Erik, Masters, Colin L, Galasko, Douglas R, Jayadev, Suman, Sanchez-Valle, Rachel, Pariente, Jeremie, Kinsella, Justin, van Dyck, Christopher H, Gauthier, Serge, Hsiung, Ging-Yuek Robin, Masellis, Mario, Dubois, Bruno, Honig, Lawrence S, Jack, Clifford R, Daniels, Alisha, Aguillón, Allegri, Ricardo, Chhatwal, Jasmeer, Day, Fox, Nick C, Huey, Edward, Ikeuchi, Takeshi, Jucker, Mathias, Lee, Jae-Hong, Levey, Allan I, Levin, Johannes, Lopera, Francisco, Roh, JeeHoon, Rosa-Neto, Pedro, Schofield, Peter R